Interestingly, regular use of aspirin after a diagnosis of CRC has been associated with a superior clinical outcome.35 There is also evidence suggesting that low daily doses of aspirin may be effective in reducing colorectal cancer risk.36 Taken together, these results suggest that COX-2 inhibitors may have potential as novel co-treatments to compliment traditional chemotherapies in advanced CRC. Here, PTGS2 is linked to colorectal carcinoma.